We have previously shown that forskolin and 3-isobutyl- 
Introduction
Cisplatin (DDP)' has been used successfully to treat several types of cancer. However, both intrinsic and acquired resis-tance to DDP occurs frequently. A variety of cell types with acquired resistance to DDP exhibit decreased accumulation of DDP as part oftheir resistant phenotype (reviewed in reference 1). Decreased DDP accumulation occurs at an early stage in the development ofresistance and accounts for the low levels of resistance found after in vivo selection with DDP (2). It is not yet known how DDP enters cells. Several lines of evidence indicate that transport is not carrier mediated (i.e., accumulation cannot be saturated or completely inhibited by structural analogues). On the other hand, DDP accumulation can be modulated by a variety ofdifferent agents indicating that DDP transport is more complex than simple passive diffusion (1) . Several recent reports have described a link between DDP and the cAMP signal transduction pathway (3, 4) . On one hand, DDP has been shown to inhibit the production of cAMP in human thyrocytes (3) . On the other hand, forskolin, an adenyl cyclase agonist, and 3-isobutyl-l-methylxanthine (IBMX), a phosphodiesterase inhibitor, caused 2.1-and 2.3-fold increases, respectively, in the short-term accumulation of DDP relative to untreated cells (4) . In contrast, the inactive analogue, 1,9-dideoxyforskolin, decreased We have now identified one such target in 2008 cells as membrane-associated tubulin on the basis of differential phosphorylation in response to treatment with forskolin or IBMX. In further support of the identification of tubulin as an intermediate in the induction of DDP uptake, we found that dipyridamole, another drug that increased DDP uptake, also induces phosphorylation of (5) , anti-MAP2 (5), anti-tau (6), anti-a-tubulin (7), and anti-,8-tubulin (8) . The anti-f3-tubulin antibody was known to react with the carboxy-terminal part of fl-tubulin on immunoblots (9) 60 Ml of protein A-Sepharose slurry (50% packed beads in RIPA buffer) was added to each tube. After another 10 min at 0C, the samples were centrifuged at 13,000 g for 1 min at room temperature. The pellet was washed three times with 0.5 ml of RIPA buffer.
Immunodetection. Immunoprecipitated proteins and proteins from lysed whole cells were separated by SDS-PAGE as described above. Proteins were transferred to PVDF membranes overnight at 14 V and blocked at room temperature for 2 h with 5% nonfat dry milk in PBS. After the blocking step, the membrane was incubated with 10 Mg/ml monoclonal mouse anti-f3-tubulin antibody in 5% nonfat dry milk for 2 h. The membrane was washed six times for 5 min each in PBS, and incubated with goat anti-mouse peroxidase conjugated antibody. fl-tubulin was visualized by developing the membrane in a solution containing diaminobenzidine at 6 g/liter and H202 at 0.03% in 50 mM Tris (pH 7.6).
Protein purification and automated microsequence analysis. Cellular proteins of broken 2008 cells were separated by SDS-PAGE with 1 mM thioglycolic acid added to the upper reservoir to help prevent amino-terminal blocking of amino acid side chains. The proteins were blotted onto PVDF membranes at 90 V for 30 min in 3-(cyclohexylamino)-l-propanesulphonic acid buffer (100 mM, pH 11). The forskolin-responsive 52-kD protein band was cut out of the membrane and subjected to microsequence analysis. Automated Edman degradations were performed on a gas phase sequencer (model 470A; Applied Biosystems, Inc., Foster City, CA) using the "03RPTH" program as supplied by the manufacturer. Phenol-thiol-hydantoin amino acid derivatives were identified using an on-line HPLC system (model 120; Applied Biosystems, Inc.). Data reduction was accomplished by computer (model 7500; Perkin Elmer Corp., Norwalk, CT) using software (Chrom 3; Perkin Elmer Corp.) (17 ( 19, 20) . Measurements were done at a final magnification of 16, 200 by placing a transparent overlay ofa 400-point grid on random micrographs of cell sections taken in the mid portion ofthe cells; i.e., including a section of the nucleus.
Colony-forming assay. Colony-forming assays were performed by seeding 300 cells per 60 mm tissue culture plastic dish, Coming Glass Works (Coming, NY). Cells were allowed to attach to the culture dishes and were then treated with taxol or colchicine for 20 h. The colonies that formed were counted after 10 d of incubation in humidified 5% CO2 at 37°C. Cell clusters containing > 50 cells were scored as a colony. min caused phosphorylation of a prominent 52-kD protein, as well as several smaller and less abundant phosphoproteins. A 2-min treatment with IBMX and dipyridamole, which are both inhibitors of phosphodiesterase, also induced phosphorylation of the 52-kD protein (Fig. 1, lanes 2, 3, 8, and 9 ), but the inactive analog of forskolin, 1,9-dideoxyforskolin, did not (data not shown). In 2008/C13*5.25 cells, forskolin, IBMX, and dipyridamole also caused increased phosphorylation ofthe 52-kD protein, however, the intensity was reduced compared to that observed in the 2008 cells.
To determine whether the cAMP-responsive 52-kD protein was membrane-associated, 32P prelabeled cells were treated with forskolin for 2 min, and membrane-associated proteins of 2008 cells were recovered by digitonin fractionation and separated by SDS-PAGE. Digitonin fractionation showed that forskolin treatment resulted in a 1.5-fold increase in phosphorylation of a 52-kD membrane-associated protein, as quantitated by the integrated intensity (absorbance x surface area) of the 52-kD band by scanning densitometry.
Microsequence analysis
Cellular proteins from 2008 cells were separated by SDS-PAGE. The proteins were transferred to PVDF membranes and the forskolin-responsive 52-kD protein band was cut out of the membrane and subjected to automated Edman degradation. The sequence of the first 19 amino-terminal amino acids is shown in Fig. 2 . This sequence is identical to that of the amino-terminal end of human fp-tubulin (22) . The amino-terminal sequence ofthe 52-kD protein was confirmed in a repeat experiment.
Comigration oftheforskolin-responsive 52-kD protein and f3-tubulin To confirm that the forskolin-responsive 52-kD protein was fp-tubulin, proteins of 32P-labeled, forskolin-treated 2008 and 2008 /C1 3 * 5.25 cells were separated by SDS-PAGE and transferred to PVDF membrane (Fig. 3) . The PVDF membrane 1 10 p52 quences of the forskolin-responsive 52-kD protein and fl-tubulin (22) are shown. was first subjected to autoradiography (Fig. 3 , lanes 1-4) and then stained with an anti-f3-tubulin antibody (Fig. 3 (Fig. 4 B) . Fig. 6 Structural characteristics ofmicrotubules. The microtubule structure of 2008 and 2008/Cl3*5.25 cells attached to the tissue culture dish was assessed by electron microscopy. Cells were cut parallel to the plane of the dish in a region including the nucleus. In both cell lines, discrete bundles ofmicrotubules were found (Fig. 9) . The volume density of microtubule bundles was 6±2% and 13±4% (Fig. 10 A) . On the other hand, 2008/C13*5.25 cells were hypersensitive to taxol (Fig. 10 B) (27) 12.5,M (25) . In addition, DDP has been shown to alter microtubule assembly by direct tubulin modification (29) and to induce changes in the cytoskeletal pattern of tumor cells (30) . DDP is also mutagenic (31, 32) and it is conceivable that during the process of selection for resistance to DDP, 2008 /C 13 * 5.25 cells have acquired alterations in tubulin structure and/or expression in response to DDP-induced mutations or tubulin damage. In several yeast models, it has been shown that the accumulation of f-tubulin in excess over a-tubulin is uniquely toxic because it interferes with normal microtubule assembly (33) . Overexpression off-tubulin leads to loss of normal microtubule structures, formation of abnormal structures, and loss of viability (33) . In the same yeast model, the excess of a-tubulin over f-tubulin was not toxic (33) . Similarly, the excess of a-tubulin over /3-tubulin present in 2008/C 13 * 5.25 cells did not cause toxicity, since these cells proliferate as well and have the same cloning efficiency as 2008 cells. Whether this imbalance can account for the altered microtubule morphology and hypersensitivity to taxol is unknown. In 2008/C1 3 * 5.25 cells, both ,Btubulin and p53 antioncogene were downregulated to a similar extent, suggesting that these two proteins might be closely associated. Indeed, immunoprecipitation with an anti-p53 antibody precipitated both p53 and 0-tubulin, confirming the association of these two proteins in 2008 cells. Similarly, in transformed mouse fibroblasts, the p53 antioncogene has been shown to coprecipitate specifically with f-tubulin (24) . Interestingly, decreased expression ofp53 has been associated with a poor response to chemotherapy in patients with lymphoma (34) . In this study, patients with deletions or translocations of the short arm ofchromosome 17, where the gene encoding p53 is located, had a poor outcome because ofa very high degree of refractoriness to chemotherapy (34) . At this juncture, it is not known by which mechanism decreased expression of p53 results in resistance to chemotherapeutic agents.
Several .25 cells were hypersensitive to taxol and cross-resistant to colchicine. This same pattern of resistance to antimitotic drugs has been found in CHO cells selected for resistance to drugs that inhibit microtubule assembly such as colcemid (35) . Thus, the DDP-resistant 2008/C13*5.25 cells had many characteristics in common with the colcemid-resistant mutants described by Minotti et al. (35) . These similarities in phenotype may, in part, be accounted for by a common target of the selecting agents DDP and colcemid. Both agents bind to tubulin and depolymerize microtubules (25, 36). The colcemid-resistant mutants were shown to have changed the conformation of tubulin in such a manner that hyperstable microtubules were formed (35) . Similarly, the microtubules of 2008/C13*5.25 cells were more dense and compact as compared with 2008 cells, and exhibited an enhanced spontaneous formation of microtubule bundles, reflecting a shift in the microtubules to a state of higher intrinsic stability. Thus, DDP-resistant and colcemid-resistant cells recruit similar defense mechanism s) to cope with damage produced by chronic selection with microtubule depolymerizing agents, and this may account for the similarities in phenotype in DDP and colcemid-resistant cells. In human leukemic cell lines, microtubule bundle formation has been shown to be related to the sensitivity of the cell line to taxol (37, 38) . Thus in 2008 /C 13 * 5.25 cells the acquired shift in the microtubules to enhanced spontaneous formation of microtubule bundles may represent the basis for the hypersensitivity to taxol. The observation that DDP-resistant ovarian carcinoma cells were hypersensitive to taxol has important clinical ramifications with respect to the treatment of DDP-resistant ovarian cancer. In this situation, taxol should be particularly effective. Indeed, phase II clinical trials with taxol in patients with advanced refractory ovarian cancer indicate that a notable proportion of responses occurred in patients who were considered to be resistant to DDP (39) .
The major mechanisms mediating resistance to DDP include impairment ofdrug uptake, elevated levels ofglutathione or metallothioneins, and enhanced DNA repair (1, 14) . Numerous laboratories have selected DDP-resistant sublines from cancer cells in vitro that accumulate less platinum, implicating a platinum accumulation deficit as an important mechanism of DDP resistance (1 ) . We 
